Astera Labs' Scorpio Momentum Meets Margin Headwinds

What happened

Astera Labs' Scorpio portfolio now drives over one-third of revenue and is on track to become its largest product line by 2026, signaling strong product adoption. However, the company's Q2'26 guidance reveals a ~330bps sequential GAAP gross margin decline to ~73%, attributed partly to a one-time customer agreement, highlighting ongoing commercial concessions. Extreme customer concentration persists, with the top five direct customers representing 90% of Q1'26 revenue and one end-customer exceeding 70% in fiscal 2025, amplifying revenue volatility. The stock trades at ~167x P/E, embedding expectations for continued hypergrowth and mid-70% margins, yet near-term margin pressure and insider selling (CEO unloaded ~615k shares in March-April) suggest limited margin of safety. The bear case—where margins stay ~73% and concentration worsens—carries a 30% probability with an implied value of $160, versus the current ~$216.

Implication

Investors should demand visible evidence that GAAP gross margin rebounds to ≥75% and Scorpio ramp materializes in 2H'26 before adding. The current valuation leaves no room for error—any incremental concession or ramp delay could trigger multiple compression toward the bear case of $160. A disciplined entry point near $180 offers a better risk/reward, with a re-assessment window of 3-6 months after Q2 and Q3 results.

Thesis delta

The narrative is shifting from 'Scorpio-driven hypergrowth with pricing power' to 'growth accompanied by margin givebacks and customer leverage.' While Scorpio's revenue contribution is increasing, the guided margin step-down and customer warrant structure indicate that near-term economics are deteriorating, not improving. The investment thesis now requires proof that margin normalization occurs alongside volume ramp, rather than assuming both will happen automatically.